[go: up one dir, main page]

EP1071333A4 - INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENE - Google Patents

INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENE

Info

Publication number
EP1071333A4
EP1071333A4 EP99912716A EP99912716A EP1071333A4 EP 1071333 A4 EP1071333 A4 EP 1071333A4 EP 99912716 A EP99912716 A EP 99912716A EP 99912716 A EP99912716 A EP 99912716A EP 1071333 A4 EP1071333 A4 EP 1071333A4
Authority
EP
European Patent Office
Prior art keywords
autoantigene
induction
immunity against
against tumor
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912716A
Other languages
German (de)
French (fr)
Other versions
EP1071333A1 (en
Inventor
Johanne Kaplan
Richard J Gregory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1071333A1 publication Critical patent/EP1071333A1/en
Publication of EP1071333A4 publication Critical patent/EP1071333A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99912716A 1998-03-20 1999-03-19 INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENE Withdrawn EP1071333A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7888998P 1998-03-20 1998-03-20
US78889P 1998-03-20
PCT/US1999/006039 WO1999046992A1 (en) 1998-03-20 1999-03-19 Induction of immunity against tumor self-antigens

Publications (2)

Publication Number Publication Date
EP1071333A1 EP1071333A1 (en) 2001-01-31
EP1071333A4 true EP1071333A4 (en) 2005-02-23

Family

ID=22146825

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912716A Withdrawn EP1071333A4 (en) 1998-03-20 1999-03-19 INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENE

Country Status (5)

Country Link
EP (1) EP1071333A4 (en)
JP (1) JP2002506618A (en)
AU (1) AU758265B2 (en)
CA (1) CA2322624A1 (en)
WO (1) WO1999046992A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391726T1 (en) * 1999-10-22 2008-04-15 Sanofi Pasteur Ltd MODIFIED GP100 AND ITS USE
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
EP1399540A2 (en) * 2001-03-12 2004-03-24 Cellcure APS Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
CA2487907A1 (en) * 2002-06-11 2003-12-18 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising a xenogenic prostate protein p501s
JP4668919B2 (en) 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド Modified CEA / B7 vector
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016775A1 (en) * 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648219A (en) * 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016775A1 (en) * 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COULIE PIERRE G: "Human tumour antigens recognized by T cells: New perspectives for anti-cancer vaccines?", MOLECULAR MEDICINE TODAY, vol. 3, no. 6, 1997, pages 261 - 268, XP002306355, ISSN: 1357-4310 *
ROMANI NIKOLAUS ET AL: "Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 196, no. 2, 1996, pages 137 - 151, XP004021269, ISSN: 0022-1759 *
See also references of WO9946992A1 *

Also Published As

Publication number Publication date
CA2322624A1 (en) 1999-09-23
WO1999046992A1 (en) 1999-09-23
AU3102999A (en) 1999-10-11
AU758265B2 (en) 2003-03-20
JP2002506618A (en) 2002-03-05
EP1071333A1 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
DE60021070D1 (en) CODING OF MICROWAVES
DE69928195D1 (en) Completion of Untrerdruck-boreholes
DE60136181D1 (en) 3'-PRODRUGS OF 2'-DEOXY-BETA-L-NUCLEOSIDES
EP1098968A4 (en) NITRILASE HOMOLOGIST
DE69916691D1 (en) Pacemaker
DE69936200D1 (en) INDUCTION HEATER
CY2012029I2 (en) NEW FORM OF 5-OMEPRAZOLE
DE69727986D1 (en) DETECTION OF EXTRAVASATION
DE69512605D1 (en) Induction hob
DE69804630D1 (en) REPRESENTATION OF PROPYLENE OXIDE
DE19983134T1 (en) Induction coil arrangement
DE69820860D1 (en) PACEMAKER
DE60126814D1 (en) INHALATION OF STICKOXIDE
DE69907146D1 (en) DIRECT OXIDATION OF CYCLOALCANES
DE69927879D1 (en) Detection of unusual waveforms
DE60023454D1 (en) LAGENMATERIALEN TENSID-MODIFIED CHELATBILDERN TREATED
DE60017816D1 (en) Pacemaker
DE59901299D1 (en) INDUCTIVE HEATING OF METALS
DE60016600D1 (en) PACEMAKER
EP1071333A4 (en) INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENE
DE59911113D1 (en) PACEMAKER
ID22276A (en) INDUCTION HEATING EQUIPMENT
ID28032A (en) TRICICLIC OF PIPERIDIN-Δ3-AS ANTAGONIS-α2
DE60025033D1 (en) HOB
DE69836690D1 (en) PACEMAKER

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20050110

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20050120

16A New documents despatched to applicant after publication of the search report

Effective date: 20050128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060510